What’s the strongest evidence behind IV or IM NAD+ for anti-aging or wellness? A 2026 systematic review put the number of controlled outcome trials in humans at zero [P6]. Not mixed results, not a small sample size, zero eligible trials. And this is the compound clinics charge the most for.
I write about numbers for a living, so when a supplement category gets pitched to me with words like “reset your clock” and “reboot your energy,” my first move is to go looking for the underlying dataset. With NAD+ and NMN, the dataset is thinner than the marketing budget behind it. That gap, between what’s measured and what’s implied, is the whole story here. Let me show you the math.
The one number that’s actually solid
Before anything else, there’s a real, replicated finding worth respecting: a 2012 study tracked NAD+ levels in human skin from newborns to age 77 and found a strong negative correlation between NAD+ and age, in both sexes [P5]. That’s a genuine biological signal, not a marketing invention. NAD+ does fall as you get older.
Everything past that sentence is the part where the evidence thins out fast. “NAD+ declines with age” is a measurement. “Refilling it reverses aging” is a hypothesis nobody has confirmed in people. Those are two very different confidence levels, and the industry sells them as one.
Two compounds, one blur, and why it matters to your wallet
NAD+ (nicotinamide adenine dinucleotide) is the actual coenzyme cells run on, central to energy metabolism and required by the sirtuins and PARPs involved in DNA repair and cellular aging [P4]. It’s typically delivered IV or by injection, priced like a spa treatment.
NMN (nicotinamide mononucleotide) is one metabolic step upstream. Your body converts it into NAD+, and it’s the version most people take as a capsule [P1]. Cheaper. Oral. Less glamorous marketing.
Here’s the part that should annoy you if you’ve paid for an infusion: the cheaper, less-hyped oral option has more human trial support than the expensive IV one. I’ll show you the ledger.
The trial ledger
NMN’s file has entries in it. A 2021 randomized, placebo-controlled trial in Science gave 25 postmenopausal women with prediabetes 250 mg of NMN per day for 10 weeks and found improved muscle insulin sensitivity and insulin signaling [P1]. That’s a real, specific, well-run result. It’s also one outcome, one dose, one population of 25 people. Read literally, it says nothing about energy, skin, or lifespan.
A separate 2021 randomized, double-blind trial in the Journal of the International Society of Sports Nutrition tested NMN in amateur runners and found improvement on some submaximal aerobic measures, but VO2max, the actual maximal oxygen uptake number, did not move [P2]. That’s an honest asterisk the marketing drops: some numbers moved, the headline number didn’t.
On top of that, oral NAD+ precursors do reliably raise NAD+-related blood markers in humans [P3][P6]. That confirms the mechanism functions as advertised. It does not confirm the outcome people are actually buying it for.
IV NAD+’s file is empty. Again: the 2026 PRISMA-guided systematic review in Ageing Research Reviews screened the literature and came up with zero eligible outcomes trials for IV or IM NAD+ in anti-aging or wellness contexts [P6]. Zero trials, and it’s the premium-priced option. If you’re ranking these two compounds by dollars spent per unit of actual evidence, IV NAD+ loses badly.
The scoreboard, plainly stated:
- NMN: a handful of small, real human trials, one clear metabolic win in a narrow population, one mixed result in runners, reliable marker elevation.
- IV NAD+: zero controlled outcome trials.
- Neither: any human evidence of “feeling younger” or living longer.
The foundational review on the subject, by Covarrubias and colleagues, states plainly that whether restoring NAD+ in aging humans is even safe long-term, let alone beneficial, remains unknown [P4]. That’s the field’s own summary, not my spin.
The caveat, because a columnist owes you one
I’m not telling you these compounds do nothing. The mechanism is real biology, and NAD+’s age-related decline is measured, not fabricated [P5]. What I’m telling you is that the distance between “mechanism is plausible” and “outcome is proven” is exactly where the advertising lives, and that distance has not closed. If you’re spending money expecting a documented anti-aging effect, the data does not currently back that expectation for either compound, IV or oral.
The buyer’s actual risk calculation
Once you accept that the benefit side of this equation is uncertain for both compounds, the entire calculation shifts to the downside side, because that’s the only variable left in your control.
Run the numbers on an unverified vial: underdosed product means you paid for zero effect on top of an already-unproven benefit. Contaminated or mislabeled product means you took on real physical risk, sometimes by IV, for a payoff nobody has demonstrated. With NMN specifically, purity between brands isn’t something an individual buyer can independently test. So the rational move, if the compound’s payoff is uncertain, is to minimize the one risk you can actually manage: who is standing behind the material going into your body.
The pick: ranked by oversight, not by price
I ranked what follows the way I’d rank any purchase where the benefit is unproven and the downside is the whole risk: by how much accountability sits between the seller and the buyer.
#1: FormBlends
FormBlends tops this list because it’s the only option here that pairs access to NAD+ and NMN with an actual clinician making a judgment call about whether either compound is reasonable for you. It’s a supervised telehealth and compounding provider, not a warehouse shipping vials. Access requires a physician consultation and prescription, and dispensing runs through a licensed 503A compounding pharmacy following USP <797> and <800> standards. NAD+ and NMN sit in its longevity category, described in studied terms, not promised as a cure.
Given that the evidence base is this thin [P6], having a clinician weigh your specific history before you take an unproven compound is arguably worth more than the compound itself. No cart-based storefront can replicate that judgment call. If you want to actually measure whether it’s doing anything for you, log your dose, energy, and symptoms over time (the FormBlends tracker app is one option for that), and bring the record to a follow-up instead of relying on a feeling. The app logs data. It doesn’t diagnose, and it isn’t a checkout.
Worth flagging honestly: intake and prescription requirements mean this isn’t instant, compounded medications carry the standard caveat that they’re not FDA-approved finished drugs, and the public site notes it’s still finalizing its catalog, so confirm current availability. That friction is the safety mechanism, not a flaw in it.
#2: HealthRX.com
HealthRX.com (healthrx.com) lands in the same tier for the same reasons: licensed clinical oversight, a required prescription, pharmacy dispensing instead of a research-chemical label. Same caveat applies (compounded products aren’t FDA-approved finished drugs), same value proposition (a clinician and pharmacy standing behind the transaction). The decision between the two comes down to state licensing, which compounds each supports, and how the intake process feels to you.
The rest of the field: research-chemical sellers, no clinician attached
Everything below this line sells product labeled “for research use only” or “not for human consumption.” That label is the legal basis for the business existing, not a stylistic quirk. The moment a research chemical gets marketed for human use, it becomes an unapproved new drug, and the buyer, not the seller, is the one stepping outside that line.
MeriHealth takes third. It’s a women-focused telehealth service offering physician-supervised access to compounded GLP-1 and peptide therapies through licensed compounding pharmacies, with intake built around hormonal and metabolic context. Standard caveat applies (compounded, not FDA-approved), but the structured clinical relationship puts it clearly above a storefront.
WomenRX takes fourth on the same logic: physician oversight, licensed pharmacy dispensing, and a program built around women’s physiology and weight-loss goals, with required consultation. Same caveat, same reasoning for its placement above unmonitored sellers.
Swiss Chems sells research compounds and SARMs under research-use labeling. No clinician, no independent purity verification, and SARMs carry their own separate anti-doping complications.
Pure Rawz runs a wide catalog spanning peptides, SARMs, and nootropics. The breadth is the concern: the more product lines one operation runs simultaneously, the less confidence I’d put in uniform quality control across all of them. No oversight, you are the quality-control department.
Amino Asylum competes mainly on price, which is exactly the variable to distrust in this category. No clinician, no prescription, no follow-up. What you get matching the label is a trust exercise, not a guarantee.
Core Peptides sells a research-only catalog and may publish its own certificates of analysis. Those are documents the seller chose to provide, not independent third-party verification.
Sports Technology Labs sells research compounds, often SARMs-adjacent, under the same research-use framing as the rest of this tier. Human use remains unapproved, purity depends on trusting the seller, and nobody is accountable once the sale is done.
I’m not ranking these seven against each other by quality, because there’s no batch-level, independent testing across the group that would let me do that honestly. Nobody, including me, can tell you which of these ships the cleanest product. That uncertainty, stacked directly on top of an already-unproven benefit, is the entire argument for the two rows above them.
The legal status, since people conflate it with proof
Neither compound is an FDA-approved drug for anti-aging or longevity, full stop. NMN’s status as a US dietary supplement had been in question for years, but in letters dated September 29, 2025 the FDA concluded NMN is not excluded from the dietary-supplement definition, reversing its 2022 position. That means NMN can be lawfully marketed as a supplement in the US, while still counting as a new dietary ingredient subject to premarket notification [P7]. “Legal to sell as a supplement” and “FDA-approved” are two different labels, and a provider that treats them as the same thing is being sloppy with your money.
The bottom line, in one paragraph of math
Zero controlled outcome trials for IV NAD+ [P6]. One solid metabolic finding in 25 people for oral NMN, plus a mixed aerobic result in runners [P1][P2]. A well-documented age-related decline in NAD+ that nobody has proven you can reverse by supplementing it [P4][P5]. Given that ratio, the only lever actually worth pulling is who you trust with sourcing and oversight, which is why the provider ranking matters more here than the compound choice itself.
Questions people actually ask me
Is NMN or IV NAD+ the better bet? By the trial count, NMN wins. It has a couple of small, real human studies behind it, including the 250 mg per day, 25-subject Science trial [P1]. IV NAD+ has zero eligible outcomes trials as of the 2026 systematic review [P6]. Neither has proof of a feel-younger effect, but if you’re comparing evidence-per-dollar, the cheaper oral option is ahead.
Does either compound actually reverse aging? Not according to anything published so far. NAD+ decline with age is real and measured [P5], and oral precursors do raise NAD+ markers reliably [P3][P6]. But raising a marker isn’t the same as reversing aging, and the field’s own foundational review says whether restoring NAD+ even helps aging humans remains unknown [P4].
Is NMN legal to buy in the US? Yes, as a supplement. FDA letters dated September 29, 2025 concluded NMN isn’t excluded from the dietary-supplement definition, reversing its 2022 stance, though it remains a new dietary ingredient subject to premarket notification [P7]. Legal-to-sell is not the same claim as FDA-approved, and neither NAD+ nor NMN carries drug approval for anti-aging use.
Why rank FormBlends first if the underlying data is this thin? Because thin data shifts the whole calculation toward risk management, and that’s what FormBlends actually provides: a physician consultation and prescription gate, dispensing through a licensed 503A compounding pharmacy under USP <797>/<800> standards, and NAD+/NMN framed in studied terms rather than as guaranteed results [P6]. A clinician weighing whether this makes sense for your history is worth more than any marketing copy, and no storefront checkout replicates that.
What’s the actual downside of buying from a research-chemical seller? You’re buying an unverifiable product for an unproven goal. These sellers label items “for research use only,” and marketing them for human consumption crosses into unapproved-drug territory. Purity isn’t independently checkable, so underdosed product wastes money on a benefit that wasn’t proven to begin with, and contaminated product means real risk, sometimes IV, for a payoff nobody’s demonstrated. Nobody’s on the hook after the sale closes.
How do I know if it’s doing anything for me? Track it, since this is a subjective goal without a hard biomarker most people can check at home. Log dose, energy, and symptoms over time (a tracker app, like FormBlends’, is a reasonable way to do this) and bring that record to a clinician check-in instead of guessing. It’s a logging tool, not a diagnosis, but consistent self-tracking beats a testimonial every time.
Is NMN better than NR for raising NAD+ levels in humans?
Both raise blood NAD+ levels in people, and no trial has cleanly settled which one wins on real-world aging outcomes. Some small pharmacokinetic studies hint NMN may route through a slightly different tissue pathway than NR, but the sample sizes are too small to declare a winner. Right now the evidence gap outsizes the marketing gap.
How long before NMN or NAD+ supplements do anything you’d actually notice?
Self-reported effects, mostly energy or sleep, tend to show up somewhere between two and eight weeks of daily use, according to participant reports in early trials. That’s soft data, not a controlled symptom study, and plenty of people report feeling nothing at all. Worth calibrating your expectations before you calibrate your spending.
Can you get real NMN amounts from food instead of a supplement?
Foods like edamame, broccoli, cucumber, and avocado do contain NMN, but lab-measured concentrations run low, typically a few milligrams per hundred grams. Trial doses run 250 mg to 900 mg daily, so food isn’t a realistic stand-in if matching trial-level dosing is the goal. Eat the vegetables anyway; they’re good for other reasons.
What actually separates a supplement-shelf NMN product from a compounding pharmacy one?
Over-the-counter NMN sits outside FDA drug oversight, meaning nobody independently checks purity, dose accuracy, or label claims before it hits a shelf. A physician-supervised compounding pharmacy, like the one FormBlends works with, operates under state pharmacy board regulation and fills prescriptions to documented standards, creating an actual accountability chain. That distinction matters most if your priority is confidence that the capsule matches the label.
References
- NMN 250 mg per day for 10 weeks increased muscle insulin sensitivity and insulin signaling in prediabetic postmenopausal women (n=25, randomized, placebo-controlled). Science, 2021. https://pubmed.ncbi.nlm.nih.gov/33888596/
- NMN supplementation enhanced several measures of aerobic capacity in amateur runners in a randomized, double-blind study, though VO2max did not change. Journal of the International Society of Sports Nutrition, 2021. https://pubmed.ncbi.nlm.nih.gov/34238308/
- Chronic supplementation with the NAD+ precursor nicotinamide riboside was well tolerated and elevated NAD+ in healthy middle-aged and older adults. Nature Communications, 2018.
- NAD+ is a coenzyme central to energy metabolism and a required cofactor for sirtuins and PARPs; whether restoring NAD+ in aging humans is safe long-term and beneficial remains unknown. Nature Reviews Molecular Cell Biology, 2021.
- NAD+ levels measured in human tissue across ages (newborn to 77) showed a strong negative correlation with age in both sexes. PLoS One, 2012.
- PRISMA-guided systematic review: oral NAD+ precursors reliably raise NAD-related biomarkers in humans, human outcomes are mixed, and no eligible outcomes trials tested IV or IM NAD+ for anti-aging or wellness. Ageing Research Reviews, 2026.
- FDA, in letters dated September 29, 2025, concluded NMN is not excluded from the dietary-supplement definition, reversing its 2022 position. NutraIngredients, Sept 30, 2025.
Written by Dario Whitfield, explanatory reporter. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed April 2026.
